SFDA Experts Set To Determine Approval Of H1N1 Vaccine
This article was originally published in PharmAsia News
China's State FDA scheduled final tests of an H1N1 flu vaccine that could mean immediate approval for release to the public. The vaccine has completed clinical trials, so the SFDA called in experts for a certification meeting with limited public and media opportunity to express concerns, but results could be determined by the end of the day. The agency is acting after a week that saw the number of H1N1 cases grew to near 3,398, although no deaths have been confirmed. (Click here for more
You may also be interested in...
Chief medical officer Samit Hirawat outlines R&D successes – though there have been some setbacks since it bought Celgene for $74bn last year – and the company’s commitment to clinical trial diversity.
Letter from department’s general counsel responds to request from the company for a pre-enforcement advisory opinion. Despite the letter, Lilly maintains its ‘limited distribution program is fully consistent with applicable laws and regulations.’
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.